Objective: Preexposure prophylaxis (PrEP) offers a promising new approach to HIV
prevention. This systematic review and meta-analysis evaluated the evidence for use of oral …

The development of antiretroviral therapy for the prevention and treatment of HIV infection
has been marked by a series of remarkable successes. However, the efforts to develop a …

Background Safe and effective long-acting injectable agents for preexposure prophylaxis
(PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options …

Background Oral pre-exposure prophylaxis has been introduced in more than 70 countries,
including many in sub-Saharan Africa, but women experience considerable barriers to daily …

Background Randomised placebo-controlled trials have shown that daily oral pre-exposure
prophylaxis (PrEP) with tenofovir–emtricitabine reduces the risk of HIV infection. However …

Background Antiretroviral preexposure prophylaxis has been shown to reduce the risk of
human immunodeficiency virus type 1 (HIV-1) infection in some studies, but conflicting …

Background Antiretroviral chemoprophylaxis before exposure is a promising approach for
the prevention of human immunodeficiency virus (HIV) acquisition. Methods We randomly …

These guidelines for the treatment of persons who have or are at risk for sexually transmitted
diseases (STDs) were updated by CDC after consultation with a group of professionals …

Background Reproductive-age women need effective interventions to prevent the
acquisition of human immunodeficiency virus type 1 (HIV-1) infection. Methods We …

HIV prevalence is increasing worldwide because people on antiretroviral therapy are living
longer, although new infections decreased from 3· 3 million in 2002, to 2· 3 million in 2012 …